Aclinical Utility of measuring [IFX] & HACA in Pts with IBD Afif w, et al. Am J Gastroenterol. 2010;105:1133-1139.

Slides:

Advertisements

Similar presentations

Osteoporosis in IBD. General Risk Factors for Osteoporosis Advancing age Advancing age Female gender Female gender Family history Family history Alcohol.

Advertisements

Literature Review Peter R. McNally, DO, FACP, FACG

University Colorado Denver Center for Human Simulation

Methotrexate Indications and Approaches

Miguel Regueiro, M.D. Professor of Medicine

Peter R. McNally, DO, FACP, FACG Lone Tree, Colorado

Literature Review Peter R. McNally, DO, FACP, FACG University Colorado Denver School of Medicine Center for Human Simulation Aurora, Colorado

Literature Review Peter R. McNally, DO, FACP, FACG University Colorado Denver School of Medicine Center for Human Simulation Aurora, Colorado

1 Literature Review Peter R. McNally, DO, FACP, FACG University Colorado at Denver School of Medicine Center for Human Simulation Aurora, Colorado

Literature Review Peter R. McNally, DO, FACP, FACG University Colorado Denver School of Medicine Center for Human Simulation Aurora, Colorado

Miguel Regueiro, M.D. Professor of Medicine

Curing HIV requires overcoming the virus’s ability to evolve There have been many attempts to cure HIV through as many different mechanisms. A common fail.

What do we do when the patient loses their response to an anti-TNF: Minor tweaks or major treatment changes? Robert N. Baldassano, MD Colman Professor.

Marla Dubinsky, MD Director, Pediatric IBD Center Associate Professor of Pediatrics Abe and Claire Levine Chair in Pediatric IBD Cedars-Sinai Medical Center.

Immunomodulators and Biologics

Jeopardy Topic Review of Rules/Scoring Procedure As of right now the house hyperlink on the page with each question comes back to this page. You can change.

When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.

Prevention of Postoperative Crohn’s disease

Joel R. Rosh, MD Director, Pediatric Gastroenterology

1 Literature Review Peter R. McNally, DO, FACP, FACG University of Colorado School of Medicine Center for Human Simulation Aurora, Colorado

1 Literature Review Peter R. McNally, DO, FACP, FACG Lone Tree, Colorado.

William J. Sandborn, MD Chief, Division of Gastroenterology

1 Unconventiional Therapies: What to do when all else fails? Scott Plevy, MD Associate Professor of Medicine, Microbiology & Immunology UNC School of Medicine.

Controversies and challenges in the clinical care of patients with IBD: You can’t always get what you want! Stephen B. Hanauer, MD University of Chicago.

Management of Biologic Therapies in IBD

Introduction to System Change Farrokh Alemi Ph.D..

Pro: Perioperative anti-TNF Biologics are safe and do not increase complications associated with surgery. Miguel Regueiro, M.D. Professor of Medicine Associate.

Vedolizumab in Pediatric IBD: We are Ready to Use It

Dyspepsia Resident Teaching Rounds Steve Radke August 11, 2003 References: Ontario Program for Optimal Therapeutics, Ontario Guidelines for PUD and GERD.

Has 4 sides all side LENGTHS congruent  LENGTHS of opposite sides congruent  both opposite sides PARALLEL  all right ANGLES

IBD Cases Stephen B. Hanauer, MD Professor of Medicine Feinberg School of Medicine Medical Director, Digestive Health Center.

You Can Never Stop a Biologic

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Xavier Roblin, MD, PhD 1, M. Rinaudo, MD 2, E. Del Tedesco, MD 1, J.M. Phelip, MD, PhD 1, C. Genin, MD, PhD 2, L. Peyrin-Biroulet, MD, PhD 3 and S. Paul,

In the name of God.

Soverini S et al. Proc ASH 2015;Abstract 346.

Obesity Trends* Among U.S. Adults BRFSS, 1985

Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.

Darts Sciences Darts Target Identification.

Figure 1 Biosimilar development process

Figure 2 Switching of biologic agents and biosimilars

Raymond Cross, MD, MS, AGAF Associate Professor of Medicine

!'!!. = pt >pt > \ ___,..___,..

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Volume 148, Issue 5, Pages e3 (May 2015)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Daniel J. Lenihan et al. BTS 2016;1:

Respondent suggestions as to how best to protocol case selection for the inflammatory bowel disease (IBD) multidisciplinary team (MDT)—application of an.

Eligibility criteria for inclusion as an expert Delphi panellist

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Pathogenesis of IBD, and the Role of Biologic Therapies

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

Predicted mortality for intra-admission change in albumin for four different admission values of albumin, calculated for a 74-year-old man with Charlson.

Respondent suggestions as to how best to protocol case selection for the inflammatory bowel disease (IBD) multidisciplinary team (MDT)—application of an.

Pie chart demonstrating relative proportion of specialists within the multidisciplinary sample—there were six consultant surgeons, six inflammatory bowel.

A loading dose decreases the time to achieve the target concentration.

Approach to 25(OH)D supplementation in patients with IBD

The impact of the addition of a faecal immunochemical test (FIT) for haemoglobin as an adjunct to clinical assessment on the pathway of patients presenting.

Probability of avoiding colectomy in paediatric severe IBD colitis.

Anti-PT IgG results from 227 patients with coughs of unknown etiology who reported the severity of cough on a scale from 0 to 10. Anti-PT IgG results from.

Effects of tube voltage, filtration, and dose rate on the color difference of the indicator. Effects of tube voltage, filtration, and dose rate on the.

Number of ventilator starts (including both noninvasive ventilation [NIV] and invasive mechanical ventilation subjects) based on age and etiology of ARF.

A summary of the different stages of adolescents and young people (AYP) with inflammatory bowel disease (IBD) transition that highlights elements that.

Endoscopic picture of ulcerative colitis with (A) Mayo grade 3 score with friable mucosa and large ulcers. Endoscopic picture of ulcerative colitis with.

Algorithm for the management of constipation in children 1 year of age and older. Algorithm for the management of constipation in children 1 year of age.

Boxplot of each etiologic subgroup with the percentage ADC reduction of affected regions compared with NAWM. ATL from carbon monoxide (CO, a small subgroup.

Presentation transcript:

Aclinical Utility of measuring [IFX] & HACA in Pts with IBD Afif w, et al. Am J Gastroenterol. 2010;105:

Results for IBD Pt with IFX Loss of Response HACA (+) Therapeutic [IFX] > 12 4wk SubTherapeutic [IFX] < 12 4wk ∆ Anti-TNFα ↑ IFX dose or Freq ∆ Anti-TNFα Inactive IBD Endo/Rad 62% of pts Active IBD Endo/Rad 38% Investigate alternative etiology Response rate 92% Failure, ∆ Rx different mechanism Response rate 17 % ↑ IFX dose or FreqResponse rate 86 % Response rate 33 % P R McNally, DO, FACP, FACG

Algorithm for IBD Pt with IFX Loss of Response HACA (+) Therapeutic [IFX] > 12 4wk SubTherapeutic [IFX] < 12 4wk ∆ Anti-TNFα ↑ IFX dose or Freq ∆ Anti-TNFα Inactive IBD Endo/Rad Active IBD Endo/Rad ∆ Anti-TNFα Investigate alternative etiology Failure, ∆ Rx different mechanism P R McNally, DO, FACP, FACG